1. Scrip

ArmaGen taps Big Pharma interest in 'Trojan horse' tech to get drugs into brain

 
• By Mandy Jackson

ArmaGen Technologies closed a $17 million Series A venture funding round with contributions from three global pharmaceutical companies and a Japanese investor for the Los Angeles-based company's platform technology designed to get both small and large molecule drugs across the blood-brain barrier (BBB).

ArmaGen Technologies closed a $17 million Series A venture funding round with contributions from three global pharmaceutical companies and a Japanese investor for the Los Angeles-based company's platform technology designed to get both small and large molecule drugs across the blood-brain barrier (BBB).

ArmaGen is hardly a startup, since it was founded in 2004 and has operated with $20 million in non-dilutive financing during the past eight years. The company intends to develop brain-penetrating recombinant protein therapeutics with a focus on orphan central nervous system (CNS) diseases

More from Alimentary/Metabolic

More from Therapeutic Category

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.